Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology ...(ard-looking statements as defined inthe...)

Date:4/11/2008

ard-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

(i) Bond GL, Hu WW, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumour Suppressor Pathway and Accelerates Tumour Formation in Humans. Cell; 2004; 119: 591-602.

(ii) Levine, A J; Hu, W; Feng, Z. The P53 pathway: what questions remain to be explored? Cell Death and Differentiation; 2006, 13(6), 1027-1036.

(iii) Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. International Journal of Biochemistry & Ce
'/>"/>

SOURCE Ortho Biotech Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
2. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
3. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
4. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
7. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
8. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
9. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
10. Progentix Orthobiology B.V. Closes Series A Financing Round
11. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings